SIBP-03 not checked

Shanghai Institute Of Biological Products · HER3 Monoclonal antibodies

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
2 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“The optimal recommended dosage (RP2D) of SIBP-03intravenous, infusion (IV), once every three weeks, 21 days as a cycle. The infusion time is 90 min (± 5 min).”In the company’s words, NCT06194656 on ClinicalTrials.gov
Tested for
Head and Neck Squamous Cell Carcinoma
Main trialPhase 2
“This phase II study will be conducted in two parts (Ⅱa and Ⅱb), with a 21-day treatment cycle until disease progression, intolerable toxicity, withdrawal of informed consent, death, initiation of new anti-tumor treatment or loss of follow-up.”In the company’s words, NCT06194656 on ClinicalTrials.gov
Other names
HER3 Monoclonal antibodies

Other drugs for Head and Neck Squamous Cell Carcinoma

All 199 drugs for Head and Neck Squamous Cell Carcinoma

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Recruiting 30 Jul 2026 Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma
Phase 1Completed 6 Dec 2022 A Phase Ⅰa Clinical Study Exploring Efficacy of SIBP-03 When Treating the Patients With Advanced Malignant Solid Tumors.
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow SIBP-03

Following is part of Solo: you see every change to SIBP-03 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in